Corcept Therapeutics Incorporated (NASDAQ:CORT) is set to post its quarterly earnings results after the market closes on Thursday, November 2nd. Analysts expect Corcept Therapeutics to post earnings of $0.09 per share for the quarter.
Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.02. Corcept Therapeutics had a return on equity of 51.45% and a net margin of 22.28%. The firm had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $31.37 million. During the same period in the previous year, the firm earned $0.01 EPS. The business’s quarterly revenue was up 80.3% on a year-over-year basis. On average, analysts expect Corcept Therapeutics to post $0.43 EPS for the current fiscal year and $0.70 EPS for the next fiscal year.
Corcept Therapeutics Incorporated (CORT) opened at 19.69 on Wednesday. Corcept Therapeutics Incorporated has a 52-week low of $6.68 and a 52-week high of $20.77. The stock’s 50 day moving average price is $18.81 and its 200-day moving average price is $14.02. The stock has a market capitalization of $2.23 billion, a PE ratio of 97.96 and a beta of 2.12.
CORT has been the topic of a number of recent research reports. Piper Jaffray Companies upped their target price on Corcept Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, September 8th. Stifel Nicolaus initiated coverage on Corcept Therapeutics in a research note on Thursday, August 31st. They issued a “buy” rating and a $20.00 target price on the stock. BidaskClub downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 4th. Ladenburg Thalmann Financial Services set a $20.00 target price on Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Finally, Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $17.17.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
What are top analysts saying about Corcept Therapeutics Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corcept Therapeutics Incorporated and related companies.